Insider buying · SEC Form 4

Insider Buying — Oct 20, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

3insider buys
$31.0Mbought in total
3companies
0by CEOs, CFOs and other chiefs
CRBGlargest: $17.1M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
CRBGCorebridge Financial, Inc.Nippon Life Insurance Co10% Owner$17.1M510,873$33.43AddedOct 19, 2026
Form 4 ↗
510,873 shares across 3 tranches at $32.28–$34.48 (wtd avg $33.43). Now $34.41 (+2.9% since buy). Strategic investor expanding position; Nippon Life has been a consistent accumulator since 2022.
IAMIambic Therapeutics, Inc.Evan Lockwood RachlinDirector$11.5M718,750$16.00AddedOct 19, 2026
Form 4 ↗
718,750 shares at $16.00 (IPO price), Oct 16 trade date, via Ascenta Capital Fund I. Now $16.34 (+2.1% since buy). Purchased on IPO day alongside preferred-to-common conversions. Strong insider conviction at deal price.
BPREBluerock Private Real Estate FundRamin KamfarDirector$2.42M194,228$12.47AddedOct 19, 2026
Form 4 ↗
194,228 shares across two days: 92,475 @ $12.5647 (Oct 15) + 101,753 @ $12.3870 (Oct 16). Now $12.25 (−1.8% since buy). Non-traded REIT; purchase via Bluerock Asset Management LLC (indirect). Routine management accumulation.

AIThe day in insider buying

SEC Form 4 Insider Scan — October 20, 2026

Scanned the last 24 hours of EDGAR Form 4 filings (Oct 19–20, 2026). 3 qualifying buys (≥ $250K, transaction type P) totalling $31.0M.

Headline filings

  • CRBG — Nippon Life Insurance Co (10% Owner) bought 510,873 shares ≈ $17.1M at $33.43 weighted avg; now $34.41 (+2.9% since buy). Large strategic holder continuing to build its position in Corebridge Financial — Nippon Life has been a consistent accumulator since its 2022 investment alongside AIG's restructuring. (filing)
  • IAM — Evan Lockwood Rachlin (Director) bought 718,750 shares ≈ $11.5M at $16.00 IPO price; now $16.34 (+2.1% since buy). Direct purchase at the Iambic Therapeutics IPO price, executed through Ascenta Capital Fund I on Oct 16 — same day the company's preferred stock converted to common. Strong conviction signal at deal price. (filing)
  • BPRE — Ramin Kamfar (Director) bought 194,228 shares ≈ $2.4M at $12.47 weighted avg; now $12.25 (−1.8% since buy). Bluerock Asset Management founder/CEO buying additional shares in the fund he manages across two days (Oct 15–16). (filing)

Notes

Themes: Institutional conviction (Nippon Life/CRBG) + biotech IPO directional bet (IAM) dominate the session. CRBG is the standout — a $17.1M add by a major strategic 10% holder at a ~2.9% premium suggests continued confidence in Corebridge's insurance run-off earnings power. IAM is a fresh IPO name; the director's $11.5M purchase at exactly the $16 offering price is a strong signal of insider alignment. BPRE is a non-traded REIT with thin secondary volume; Kamfar's purchase is routine but consistent with prior monthly adds. No cluster activity at any single operating company. October earnings season context: none of these three companies had recent major earnings releases within 5 days of the trade dates.

Most-bought stocks, last 30 days

  • LEN $405M · 2 buys, 2 insidersLennar Corporation
  • GME $104M · 8 buys, 3 insidersGameStop Corp.
  • CRBG $83.3M · 6 buys, 2 insidersCorebridge Financial, Inc.
  • GRAB $60.6M · 3 buys, 3 insidersGrab Holdings Ltd
  • GPI $56.8M · 3 buys, 2 insidersGroup 1 Automotive Inc.
  • BORR $51.3M · 8 buysBorr Drilling Ltd
  • ADRX $37.3M · 2 buys, 2 insidersADARx Pharmaceuticals, Inc.
  • BPRE $22.2M · 4 buysBluerock Private Real Estate Fund
  • QVCG $16.7M · 1 buyQVC Group, Inc.
  • AVR $16.6M · 4 buysAnteris Technologies Global Corp.
  • IAM $11.5M · 1 buyIambic Therapeutics, Inc.
  • COUR $11.4M · 1 buyCoursera, Inc.
  • PSUS $9.61M · 1 buyPershing Square USA, Ltd.
  • NYAX $9.22M · 2 buysNayax Ltd.
  • ENHA $6.99M · 1 buyEnhanced Group Inc
  • APLD $6.66M · 2 buys, 2 insidersApplied Digital Corp.
  • NFE $5.02M · 1 buyNew Fortress Energy Inc
  • GPUS $5.00M · 1 buyHyperscale Data, Inc.
  • GOLD $3.94M · 2 buys, 2 insidersGold.com, Inc.
  • ACCV $3.66M · 1 buyAccelevation Holdings Corp.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.